<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1614">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784754</url>
  </required_header>
  <id_info>
    <org_study_id>UBMELCOVID19-P</org_study_id>
    <secondary_id>UL1TR001412</secondary_id>
    <nct_id>NCT04784754</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19</brief_title>
  <official_title>A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot placebo-controlled randomized double-blind trial of Melatonin in outpatients with&#xD;
      COVID-19 infection to evaluate Safety, Efficacy and Dose-ranging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown in the blood of patients with COVID-19 there was a marked increase in the&#xD;
      cytokines and chemokines interleukin 1β (IL-1β), interferon-γ (IFN-γ), interferon-inducible&#xD;
      protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1) and interleukin-4 (IL-4).&#xD;
      Consequently, treatments that reduce cytokine/chemokine production that result in a less&#xD;
      severe course of disease could be potentially beneficial. Melatonin, a pineal hormone, has&#xD;
      been shown to have anti-inflammation, anti-oxidation and immune enhancing features. In&#xD;
      multiple animal models of lung injury, Melatonin supplementation has been shown to decrease&#xD;
      the number of inflammatory cells, reduce the levels of the cytokines IL-4, IL-5, IL-13 and&#xD;
      TNF-a and reduce nitric oxide and hydroxyl radical concentrations. We propose a dose ranging&#xD;
      pilot study to assess the safety and efficacy of melatonin in reducing hospitalization in&#xD;
      COVID-19 patients with mild-moderate disease. A total of 50 participants will be randomized&#xD;
      to the intervention arm (melatonin: 3 mg, or 30 mg three times a day for 14 days) or control&#xD;
      arm (placebo) in a 2:2:1 fashion using a permuted block randomization scheme. Analyses will&#xD;
      be performed with a focus on estimation of specific clinically important parameters,&#xD;
      including safety and preliminary evidence of activity, for planning of a subsequent&#xD;
      definitive comparative trial designed to fully assess efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-controlled randomized double-blind trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>42 days</time_frame>
    <description>Evaluate the incidence of serious adverse effects and discontinuation secondary to toxicity through 42 days of follow-up as compared to the control arm as assessed by: Cumulative incidence of serious adverse events (SAEs), Cumulative incidence of Grade 3 and 4 adverse events (AEs), Discontinuation or temporary suspension of the investigational medication (for any reason).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 related hospitalization</measure>
    <time_frame>42 days</time_frame>
    <description>Incidence of COVID-19 related hospitalization at 42 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 related symptoms</measure>
    <time_frame>42 days</time_frame>
    <description>COVID-19 related symptoms as self-reported and on interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of resolution of COVID-19 related symptoms</measure>
    <time_frame>up to 42 days</time_frame>
    <description>Change from baseline (day 1) as assessed to days 3, 7, 14, 28 and 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>42 days</time_frame>
    <description>42-day mortality</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin capsules will be prepared using hypromellose capsules containing 3 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin capsules will be prepared using hypromellose capsules containing 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.</description>
    <arm_group_label>Melatonin 3 mg</arm_group_label>
    <arm_group_label>Melatonin 30 mg</arm_group_label>
    <other_name>5-methoxy-N-acetyl tryptamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Microcrystalline Cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant female adult ≥18 years of age at time of enrollment.&#xD;
&#xD;
          2. Women of childbearing potential must agree to use at least one primary form of&#xD;
             contraception for the duration of the study.&#xD;
&#xD;
          3. Positive testing for COVID-19 infection by standard RT-PCR assay or equivalent test.&#xD;
&#xD;
          4. Meets criteria for mild or moderate COVID-19 disease&#xD;
&#xD;
          5. Subject provides written informed consent prior to initiation of any study procedures.&#xD;
&#xD;
          6. Understands and agrees to comply with planned study procedures.&#xD;
&#xD;
          7. Agrees to the collection and storage of saliva samples per protocol.&#xD;
&#xD;
          8. Subject can provide an emergency contact who the study team can contact in case the&#xD;
             subject is not reachable on any of the study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe (eGFR&lt;30 ml/min) and moderate (eGFR 30-60 ml/min) chronic kidney disease or&#xD;
             requiring dialysis&#xD;
&#xD;
          2. Severe hepatic insufficiency defined as one or more of the following: Cirrhosis&#xD;
             diagnosis, Serum ALT &gt; 3x ULN or Alkaline phosphatase &gt;3x ULN or bilirubin &gt;2x ULN in&#xD;
             the absence of Gilbert's or hemolysis, Uncontrolled acute or chronic liver disease&#xD;
             (e.g. acute hepatitis A, unstable autoimmune hepatitis)&#xD;
&#xD;
          3. Pregnancy or breast feeding.&#xD;
&#xD;
          4. History of a seizure disorder.&#xD;
&#xD;
          5. Patient is taking Fluvoxamine, Capmatinib, Ciprofloxacin (Systemic), Deferasirox,&#xD;
             Givosiran, Methoxsalen (Systemic), Mexiletine, Rucaparib, Stiripentol, Thiabendazole,&#xD;
             Vemurafenib, Methoxsalen, Sodium oxybate or Echinacea.&#xD;
&#xD;
          6. Allergy to the study medication&#xD;
&#xD;
          7. Currently taking melatonin&#xD;
&#xD;
          8. Currently taking high dose (&gt;500 mg/day) Vitamin C.&#xD;
&#xD;
          9. Meets criteria for Severe or Critical COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margarita L Dubocovich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margarita L Dubocovich, PhD</last_name>
    <phone>716 829 3048</phone>
    <email>mdubo@buffalo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanjay Sethi, MD</last_name>
    <phone>716 888 4864</phone>
    <email>ssethi@buffalo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html</url>
    <description>CDC COVID-19 Information</description>
  </link>
  <reference>
    <citation>Aliasgharzadeh A, Farhood B, Amini P, Saffar H, Motevaseli E, Rezapoor S, Nouruzi F, Shabeeb DH, Eleojo Musa A, Mohseni M, Moradi H, Najafi M. Melatonin Attenuates Upregulation of Duox1 and Duox2 and Protects against Lung Injury following Chest Irradiation in Rats. Cell J. 2019 Oct;21(3):236-242. doi: 10.22074/cellj.2019.6207. Epub 2019 Jun 15.</citation>
    <PMID>31210428</PMID>
  </reference>
  <reference>
    <citation>Andersen LP, Gögenur I, Rosenberg J, Reiter RJ. The Safety of Melatonin in Humans. Clin Drug Investig. 2016 Mar;36(3):169-75. doi: 10.1007/s40261-015-0368-5. Review.</citation>
    <PMID>26692007</PMID>
  </reference>
  <reference>
    <citation>Bazyar H, Gholinezhad H, Moradi L, Salehi P, Abadi F, Ravanbakhsh M, Zare Javid A. The effects of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and inflammatory markers in type 2 diabetes mellitus patients with chronic periodontitis: a double-blind, placebo-controlled trial. Inflammopharmacology. 2019 Feb;27(1):67-76. doi: 10.1007/s10787-018-0539-0. Epub 2018 Oct 16.</citation>
    <PMID>30328031</PMID>
  </reference>
  <reference>
    <citation>Chen CF, Wang D, Reiter RJ, Yeh DY. Oral melatonin attenuates lung inflammation and airway hyperreactivity induced by inhalation of aerosolized pancreatic fluid in rats. J Pineal Res. 2011 Jan;50(1):46-53. doi: 10.1111/j.1600-079X.2010.00808.x. Epub 2010 Oct 22.</citation>
    <PMID>20964706</PMID>
  </reference>
  <reference>
    <citation>Cheung CY, Poon LL, Ng IH, Luk W, Sia SF, Wu MH, Chan KH, Yuen KY, Gordon S, Guan Y, Peiris JS. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005 Jun;79(12):7819-26.</citation>
    <PMID>15919935</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Kim JY, Lee YD, Kim BJ, Kim SP, Kim DH, Jo KJ, Lee SK, Lee KH, Baik HW. Melatonin improves inflammatory cytokine profiles in lung inflammation associated with sleep deprivation. Mol Med Rep. 2012 May;5(5):1281-4. doi: 10.3892/mmr.2012.814. Epub 2012 Feb 29.</citation>
    <PMID>22377793</PMID>
  </reference>
  <reference>
    <citation>Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, Nicholls JM, Peiris JS, Lau YL. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005 Oct 1;106(7):2366-74. Epub 2005 Apr 28.</citation>
    <PMID>15860669</PMID>
  </reference>
  <reference>
    <citation>Pedreira PR, García-Prieto E, Parra D, Astudillo A, Diaz E, Taboada F, Albaiceta GM. Effects of melatonin in an experimental model of ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2008 Nov;295(5):L820-7. doi: 10.1152/ajplung.90211.2008. Epub 2008 Sep 19.</citation>
    <PMID>18805959</PMID>
  </reference>
  <reference>
    <citation>Peng Z, Zhang W, Qiao J, He B. Melatonin attenuates airway inflammation via SIRT1 dependent inhibition of NLRP3 inflammasome and IL-1β in rats with COPD. Int Immunopharmacol. 2018 Sep;62:23-28. doi: 10.1016/j.intimp.2018.06.033. Epub 2018 Jun 30.</citation>
    <PMID>29990691</PMID>
  </reference>
  <reference>
    <citation>Sánchez-López AL, Ortiz GG, Pacheco-Moises FP, Mireles-Ramírez MA, Bitzer-Quintero OK, Delgado-Lara DLC, Ramírez-Jirano LJ, Velázquez-Brizuela IE. Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis. Arch Med Res. 2018 Aug;49(6):391-398. doi: 10.1016/j.arcmed.2018.12.004. Epub 2018 Dec 27.</citation>
    <PMID>30595364</PMID>
  </reference>
  <reference>
    <citation>Shang Y, Xu SP, Wu Y, Jiang YX, Wu ZY, Yuan SY, Yao SL. Melatonin reduces acute lung injury in endotoxemic rats. Chin Med J (Engl). 2009 Jun 20;122(12):1388-93.</citation>
    <PMID>19567158</PMID>
  </reference>
  <reference>
    <citation>Shin IS, Park JW, Shin NR, Jeon CM, Kwon OK, Kim JS, Kim JC, Oh SR, Ahn KS. Melatonin reduces airway inflammation in ovalbumin-induced asthma. Immunobiology. 2014 Dec;219(12):901-8. doi: 10.1016/j.imbio.2014.08.004. Epub 2014 Aug 10.</citation>
    <PMID>25161126</PMID>
  </reference>
  <reference>
    <citation>Wang S, Zhao Z, Feng X, Cheng Z, Xiong Z, Wang T, Lin J, Zhang M, Hu J, Fan Y, Reiter RJ, Wang H, Sun D. Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition. J Cell Mol Med. 2018 Oct;22(10):5132-5144. doi: 10.1111/jcmm.13802. Epub 2018 Jul 31.</citation>
    <PMID>30063115</PMID>
  </reference>
  <reference>
    <citation>Wu GC, Peng CK, Liao WI, Pao HP, Huang KL, Chu SJ. Melatonin receptor agonist protects against acute lung injury induced by ventilator through up-regulation of IL-10 production. Respir Res. 2020 Mar 6;21(1):65. doi: 10.1186/s12931-020-1325-2.</citation>
    <PMID>32143642</PMID>
  </reference>
  <reference>
    <citation>Wu WS, Chou MT, Chao CM, Chang CK, Lin MT, Chang CP. Melatonin reduces acute lung inflammation, edema, and hemorrhage in heatstroke rats. Acta Pharmacol Sin. 2012 Jun;33(6):775-82. doi: 10.1038/aps.2012.29. Epub 2012 May 21.</citation>
    <PMID>22609835</PMID>
  </reference>
  <reference>
    <citation>Zhao X, Sun J, Su W, Shan H, Zhang B, Wang Y, Shabanova A, Shan H, Liang H. Melatonin Protects against Lung Fibrosis by Regulating the Hippo/YAP Pathway. Int J Mol Sci. 2018 Apr 9;19(4). pii: E1118. doi: 10.3390/ijms19041118.</citation>
    <PMID>29642520</PMID>
  </reference>
  <reference>
    <citation>Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, Liu C, Reiter RJ. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020 Jun 1;250:117583. doi: 10.1016/j.lfs.2020.117583. Epub 2020 Mar 23. Review.</citation>
    <PMID>32217117</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Margarita L. Dubocovich, PhD</investigator_full_name>
    <investigator_title>SUNY Distinguished Professor</investigator_title>
  </responsible_party>
  <keyword>Melatonin</keyword>
  <keyword>COVID-19</keyword>
  <keyword>outpatient</keyword>
  <keyword>SARS-CoV-2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

